BACKGROUND: S100A12, also known as EN-RAGE (extracellular newly identified receptor for advanced glycation end products binding protein) is a ligand for RAGE, and has been proposed to contribute to the development of atherosclerosis. In this study, we examined the plasma S100A12 concentration in patients with ESRD and undergoing hemodialysis (HD) and evaluated the relation between S100A12 level and carotid intimal media thickness (IMT) by ultrasound. METHODS: We measured plasma S100A12 concentration in 72 HD patients and 42 control subjects. IMT of the carotid artery was measured by high-resolution B-mode ultrasonography in 46 HD patients. RESULTS: The mean plasma S100A12 level was 2.3-fold higher in HD patients than in control subjects (25.0 +/- 2.32 vs. 10.7 +/- 0.97 ng/ml, p < 0.001). Stepwise multiple regression analysis identified circulating white blood cell count as a positive independent determinant and total cholesterol and serum albumin levels as negative independent determinants of plasma S100A12 concentration. The maximum IMT was positively correlated with plasma S100A12 level. Stepwise multiple regression analysis also identified plasma S100A12 as a significant independent determinant of the maximum IMT. CONCLUSION: These findings suggest that S100A12 protein is involved in the acceleration of atherosclerosis in HD patients. Copyright 2008 S. Karger AG, Basel.
BACKGROUND:S100A12, also known as EN-RAGE (extracellular newly identified receptor for advanced glycation end products binding protein) is a ligand for RAGE, and has been proposed to contribute to the development of atherosclerosis. In this study, we examined the plasma S100A12 concentration in patients with ESRD and undergoing hemodialysis (HD) and evaluated the relation between S100A12 level and carotid intimal media thickness (IMT) by ultrasound. METHODS: We measured plasma S100A12 concentration in 72 HDpatients and 42 control subjects. IMT of the carotid artery was measured by high-resolution B-mode ultrasonography in 46 HDpatients. RESULTS: The mean plasma S100A12 level was 2.3-fold higher in HDpatients than in control subjects (25.0 +/- 2.32 vs. 10.7 +/- 0.97 ng/ml, p < 0.001). Stepwise multiple regression analysis identified circulating white blood cell count as a positive independent determinant and total cholesterol and serum albumin levels as negative independent determinants of plasma S100A12 concentration. The maximum IMT was positively correlated with plasma S100A12 level. Stepwise multiple regression analysis also identified plasma S100A12 as a significant independent determinant of the maximum IMT. CONCLUSION: These findings suggest that S100A12 protein is involved in the acceleration of atherosclerosis in HDpatients. Copyright 2008 S. Karger AG, Basel.
Authors: Shijie Li; Paul Kievit; Anna-Karin Robertson; Ganesh Kolumam; Xiumin Li; Karin von Wachenfeldt; Christine Valfridsson; Sherry Bullens; Ilhem Messaoudi; Lindsay Bader; Kyra J Cowan; Amrita Kamath; Nicholas van Bruggen; Stuart Bunting; Björn Frendéus; Kevin L Grove Journal: Mol Metab Date: 2013-06-11 Impact factor: 7.422
Authors: Marion A Hofmann Bowman; Joseph Gawdzik; Usama Bukhari; Aliya N Husain; Peter T Toth; Gene Kim; Judy Earley; Elizabeth M McNally Journal: Arterioscler Thromb Vasc Biol Date: 2010-10-21 Impact factor: 8.311
Authors: Naohito Isoyama; Anna Machowska; Abdul Rashid Qureshi; Tae Yamamoto; Björn Anderstam; Olof Heimburger; Peter Barany; Peter Stenvinkel; Bengt Lindholm Journal: Perit Dial Int Date: 2015-10-22 Impact factor: 1.756